During the last session, 4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s traded shares were 0.32 million, with the beta value of the company hitting 2.94. At the end of the trading day, the stock’s price was $23.25, reflecting an intraday loss of -1.19% or -$0.28. The 52-week high for the FDMT share is $36.25, that puts it down -55.91 from that peak though still a striking 59.4% gain since the share price plummeted to a 52-week low of $9.44. The company’s market capitalization is $1.19B, and the average trade volume was 1.21 million shares over the past three months.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
4D Molecular Therapeutics Inc (FDMT) registered a -1.19% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.19% in intraday trading to $23.25, hitting a weekly high. The stock’s 5-day price performance is -7.92%, and it has moved by -35.18% in 30 days. Based on these gigs, the overall price performance for the year is 13.03%.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
Statistics show that 4D Molecular Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. 4D Molecular Therapeutics Inc (FDMT) shares have gone up 124.20% during the last six months, with a year-to-date growth rate less than the industry average at -17.44% against 10.40. In the rating firms’ projections, revenue will decrease -72.20% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 780k as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 760k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 298k and 850k respectively. In this case, analysts expect current quarter sales to grow by 161.70% and then drop by -10.60% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -46.35%. While earnings are projected to return -13.58% in 2024.
FDMT Dividends
4D Molecular Therapeutics Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
